Zai Lab (ZLAB) Long-Term Deferred Tax (2025 - 2026)

Zai Lab (ZLAB) reported Long-Term Deferred Tax of $3.4 million for Q1 2026, up 1.59% sequentially from $3.4 million in Q4 2025.

Zai Lab (ZLAB) Long-Term Deferred Tax (2025 - 2026) Analysis & Trends

Zai Lab (ZLAB) has 2 years of Long-Term Deferred Tax data on file, last reported at $3.4 million in Q1 2026.

For the quarter ending Q1 2026, Long-Term Deferred Tax changed N/A year-over-year to $3.4 million; the trailing twelve-month figure through Mar 2026 stood at $3.4 million (changed N/A YoY), and the FY2025 full-year result was $3.4 million, changed N/A from the prior year.
Long-Term Deferred Tax grew to $3.4 million in Q1 2026, from $3.4 million in the prior quarter.
In the past five years, Long-Term Deferred Tax ranged from a high of $3.4 million in Q1 2026 to a low of $3.4 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	Zai Lab	21.37 Bn	21.37 Bn	-34.26 Mn

Download Data

Date	Value
Mar 31, 2026	3.44 Mn
Dec 31, 2025	3.39 Mn